



ALK to present at Jefferies Autumn 2015 Global Healthcare Conference in London

November 5, 2015

Copenhagen, 2015-11-06 12:15 CET (GLOBE NEWSWIRE) --

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the Company will present at the Jefferies Autumn 2015 Global Healthcare Conference at The May Fair Hotel in London.

Søren Daniel Niegel, Executive Vice President Commercial Operations, will provide an overview of the Company and its key programmes on Wednesday, 18 November at 4.40 PM (GMT).

ALK-Abelló A/S

For further information please contact:

Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Janet Dally, tel. +1 609-466-0466, mobile 732-319-2833

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck, Torii, Abbott and bioCSL to commercialise sublingual allergy immunotherapy tablets in North America, Japan, Russia, Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen. Find more information at www.alk.net.